Anika Therapeutics, Inc.ANIKEarnings & Financial Report
ANIK Q1 FY2026 Key Financial Metrics
Revenue
$29.6M
Gross Profit
$19.0M
Operating Profit
$5.1M
Net Profit
N/A
Gross Margin
64.2%
Operating Margin
17.3%
Net Margin
N/A
YoY Growth
13.2%
EPS
$0.27
Anika Therapeutics, Inc. Q1 FY2026 Financial Summary
Anika Therapeutics, Inc. reported revenue of $29.6M (up 13.2% YoY) for Q1 FY2026, with a net profit of N/A (N/A margin). Cost of goods sold was $10.6M, operating expenses totaled $13.9M.
Key Financial Metrics
| Total Revenue | $29.6M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 64.2% |
| Operating Margin | 17.3% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Anika Therapeutics, Inc. Q1 FY2026 revenue of $29.6M breaks down across 2 segments, led by OEM Channel at $17.0M (57.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| OEM Channel | $17.0M | 57.4% |
| Commercial Channel | $12.6M | 42.6% |
Anika Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Anika Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as OEM Channel and Commercial Channel) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| OEM Channel | $17.0M | $17.3M | $15.8M | $16.3M |
| Commercial Channel | $12.6M | $13.3M | $12.0M | $11.9M |
Anika Therapeutics, Inc. Annual Revenue by Year
Anika Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $112.8M).
Anika Therapeutics, Inc. Quarterly Revenue & Net Profit History
Anika Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $29.6M | +13.2% | N/A | N/A |
| Q4 FY2025 | $30.6M | +0.0% | $292.0K | 1.0% |
| Q3 FY2025 | $27.8M | -5.9% | $-2.3M | -8.4% |
| Q2 FY2025 | $28.2M | -8.2% | $-4.0M | -14.1% |
| Q1 FY2025 | $26.2M | -9.8% | $-4.9M | -18.6% |
| Q4 FY2024 | $30.6M | +1155.6% | $-21.9M | -71.4% |
| Q3 FY2024 | $29.6M | -28.7% | $-29.9M | -101.2% |
| Q2 FY2024 | $30.7M | -30.6% | $-88.0K | -0.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.7M | $29.6M | $30.6M | $26.2M | $28.2M | $27.8M | $30.6M | $29.6M |
| YoY Growth | -30.6% | -28.7% | 1155.6% | -9.8% | -8.2% | -5.9% | 0.0% | 13.2% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $262.7M | $231.4M | $202.7M | $190.6M | $187.7M | $189.4M | $190.3M | $179.4M |
| Liabilities | $52.3M | $51.5M | $48.8M | $42.2M | $40.0M | $42.6M | $46.8M | $45.5M |
| Equity | $210.3M | $179.9M | $154.0M | $148.4M | $147.7M | $146.8M | $143.5M | $133.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.1M | $5.0M | $1.6M | $-130000 | $-189000 | $6.9M | $4.6M |